Pheton (NASDAQ:PTHL) vs. Oncology Institute (NASDAQ:TOI) Financial Comparison

Oncology Institute (NASDAQ:TOI) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Risk and Volatility

Oncology Institute has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the S&P 500.

Insider & Institutional Ownership

36.9% of Oncology Institute shares are held by institutional investors. 8.5% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Oncology Institute and Pheton”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$393.41 million	0.67	-$64.66 million	($0.64)	-4.16
Pheton	$305,215.00	9.28	-$660,000.00	N/A	N/A

Pheton has lower revenue, but higher earnings than Oncology Institute.

Analyst Ratings

This is a breakdown of recent ratings for Oncology Institute and Pheton, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1	0	3	1	2.80
Pheton	1	0	0	0	1.00

Oncology Institute presently has a consensus price target of $6.50, suggesting a potential upside of 143.90%. Given Oncology Institute’s stronger consensus rating and higher possible upside, research analysts clearly believe Oncology Institute is more favorable than Pheton.

Profitability

This table compares Oncology Institute and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-13.21%	-1,527.21%	-35.30%
Pheton	N/A	N/A	N/A

Summary

Oncology Institute beats Pheton on 7 of the 13 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.